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Dstudies with longer follow-up are necessary to demonstrate
whether these differences have a significant clinical effect.
With the present study, we wish to highlight that surgical
aortic valve replacement is still the best choice for patients
with aortic valve stenosis. However, new therapeutic
options such as TAVR and SU-AVR can provide good
results in select patients. A center that is able to offer their
patients all these therapeutic alternatives can select the most
appropriate technique, tailoring the choice to each patient
and considering all crucial characteristics such as age,
comorbidities, frailty, and anatomy. A particularly careful
evaluation is needed for patients in the ‘‘gray zone,’’ who
can benefit from either technique. An experienced ‘‘aortic
team’’ will be able to make the most appropriate choice.
The limitations of the present study were mainly related
to the retrospective nature, the different procedures
conducted at different centers, the inclusion of TA-
TAVR–only patients, and the small number of patients in
the SU-AVR cohort.
In conclusion, our data have shown that no main differ-
ences exist in the outcomes among SAVR, TA-TAVR, and
SU-AVR. SAVRwas associated with a significant reduction
in postoperative AR compared with TA-TAVR. The latter,
however, showed lower transaortic gradients. A trend was
seen toward less AR in the SU-AVR group than in the
TA-TAVR group; however, this difference was not statisti-
cally significant. Future, larger, and, possibly, prospective
studies are needed to confirm our preliminary results.
The authors are grateful to Leila Hosseinian, MD, and Gianluca
Torregrossa, MD, for their kind and precious assistance in lan-
guage editing and manuscript revision.References
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Dr Martin Misfeld (Leipzig, Germany). I would like to thank
the American Association for Thoracic Surgery (AATS) for the
opportunity to discuss the report by Dr D’Onofrio and colleagues
and Dr D’Onofrio for supplying me with the report in a timely
manner.
The present study is a comparison of 566 patients undergoing
TA-TAVR in 20 Italian cardiac surgery centers and 38 patients
undergoing SAVR in 3 centers and 349 patients undergoinggery c November 2013
D’Onofrio et al Acquired Cardiovascular Disease
A
C
Dconventional aortic valve replacement in 1 center. It represents
an extension of a study presented at last year’s AATS
meeting and has recently been published in the Journal of
Thoracic and Cardiovascular Surgery, in which comparisons
were made between patients receiving a transapical Edwards
SAPIEN valve and those who underwent implantation of the
Perceval S sutureless valve. To the best of my knowledge, the
present report is the first to compare these 3 patient groups
simultaneously.
Dr D’Onofrio and colleagues have used sophisticated pro-
pensity score matching to compare these 3 groups. However, the
overlapping treatment period of the 3 patient groups and the lack
of randomization very likely resulted in significant differences
among the groups. The patient factors that were not measured,
such as frailty, porcelain aorta, or other risk factors for conven-
tional surgery, were undoubtedly different among the groups.
Although these unmeasured patient factors could explain the
elevated mortality observed in the TAVR group, they are less likely
to have affected the observed hemodynamic differences among the
groups (ie, the lower transvalvular gradient and greater incidence
of AR in the TAVR group).
I have 4 questions for the authors.
First, what were the criteria for deciding whether patients
underwent TA-TAVR or sutureless valve implantation in the
elderly high-risk subgroup and what patient-related features would
have made you decide that 1 technique would be definitely more
suitable than the other?
Second, the paravalvular leak rate for the sutureless group was
greater than that usually mentioned in published studies. Do you
have an explanation for this?
Third, did the sutureless valve patients have lower crossclamp
and cardiopulmonary bypass times than those undergoing
conventional AVR?
Finally, is it time for a randomization trial between sutureless
valves and TAVR?The Journal of Thoracic and CarOnce again, I would like to thank the Association for the honor
of being able to discuss this unique and important study.
Dr D’Onofrio. Thank you for your kind comments and
questions.
Talking about your first question, actually, each of these tech-
niques has pros and cons for high-risk patients. I’m talking about
transcatheter and sutureless aortic valve replacement.
Transcatheter is, of course, less invasive. It can be performed on
the awake patient, especially if performed through transfemoral
access, and does not require cardiopulmonary bypass or aortic
crossclamping; thus, it is definitely less invasive. However, the
rate of paravalvular leak is still high.
In contrast, SAVR requires cardiopulmonary bypass and aortic
crossclamping. With this technique, the hemodynamic results in
terms of paravalvular leakage have been much better.
I think that the choice between these 2 alternative techniques
should be tailored to the characteristics of each patient,
considering age, comorbidities, and, as you mentioned, frailty
and other factors that usually are not included in risk scores.
Regarding the incidence of paravalvular leak, it was high in the
sutureless group, that is true, but evenmildARwas included in these
analyses. The patients with mild AR were actually the first 30 pa-
tients who received the sutureless valve in our country. It was at
the very beginning of the learning curve. Currently, we have been
observing a progressive decrease in paravalvular leakage as our
experience in sizing and the implantation technique has improved.
The crossclamp and cardiopulmonary bypass time was
44 minutes and 69 minutes, respectively, in the sutureless group.
Again, this was the very beginning of our experience, and we
now are observing that the crossclamp time in these patients can
be as low as 20 minutes with the improvement in experience.
Of course, a trial would be an excellent idea. However, as you
mentioned, these are 3 techniques for 3 different groups of
patients. Thus, it would not be easy to design a prospective study
to include all 3 techniques in similar patients.diovascular Surgery c Volume 146, Number 5 1071
